16th week of 2011 patent applcation highlights part 23 |
Patent application number | Title | Published |
20110091450 | METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2011-04-21 |
20110091451 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 2011-04-21 |
20110091452 | 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies - The present invention relates to 4,5-dihydromacbecin analogues to the formula (IA) or (IB), or a pharmaceutically acceptable salt there of: wherein: R | 2011-04-21 |
20110091453 | METHODS OF ADMINISTERING/DOSING CD2 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISORDERS OR INFLAMMATORY DISEASES - The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes. | 2011-04-21 |
20110091454 | METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES - Polypeptide sequences and polynucleotide sequences are provided. Also provided are annotative information concerning such sequences and uses for these sequences. | 2011-04-21 |
20110091455 | ANTIBODIES TO MYOSTATIN - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2011-04-21 |
20110091456 | TREATMENT OF NEUROLOGICAL CONDITIONS - The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF or G-CSFR, a soluble G-CSFR or a G-CSF-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding G-CSF. | 2011-04-21 |
20110091457 | METHOD FOR PROGNOSTICATING THE CLINICAL RESPONSE OF A PATIENT TO B-LYMPHOCYTE INHIBITING OR DEPLETING THERAPY - The invention relates to methods for predicting a clinical response to B-lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B-lymphocyte inhibiting or depleting therapy. More in particular, the invention relates to a method for prognosticating the clinical response of a patient to treatment with a soluble BCID or TCID agent, said method comprising the steps of obtaining at least two samples from said patient wherein a first sample has not been exposed to a soluble BCID or TCID agent and wherein at least a second sample has been exposed to a soluble BCID or TCID agent, determining the level of an IFN-I type response in said at least two samples, comparing the level of the IFN-I type response in said first sample with the level of the IFN-1 type response in said at least second sample and prognosticating said clinical response from said comparison. | 2011-04-21 |
20110091458 | ANTI-IL 13 HUMAN ANTIBODIES - The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. | 2011-04-21 |
20110091459 | IMIDAZOLE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M3 - The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2011-04-21 |
20110091460 | RECEPTOR-TARGETING REAGENTS - The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders. | 2011-04-21 |
20110091461 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications. | 2011-04-21 |
20110091462 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING AND USES THEREOF - In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided. | 2011-04-21 |
20110091463 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2011-04-21 |
20110091464 | NOVEL PEPTIDES AND PROTEIN AND USES THEREOF - The present invention relates to a novel gene encoding a protein termed Coiled Coil Domain Containing 95 (CCDC95) or a peptide fragments thereof. The present invention also relates to the use of CCDC95 in Modulation of RGK small binding protein via altering concentration or sub-cellular localisation of RGK small binding protein with CCDC95 or a peptide fragments thereof. | 2011-04-21 |
20110091465 | POLYPEPTIDES - The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies. | 2011-04-21 |
20110091466 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 2011-04-21 |
20110091467 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION - The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling. | 2011-04-21 |
20110091468 | Connective tissue growth factor antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 2011-04-21 |
20110091469 | ATTRACTIN/MAHOGANY-LIKE POLYPEPTIDES, POLYNUCLEOTIDES, ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides. | 2011-04-21 |
20110091470 | ANTI-FLT3 ANTIBODIES - The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate. | 2011-04-21 |
20110091471 | TREATMENT METHOD FOR EPITHELIAL CANCEROUS ORGANISM - It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:
| 2011-04-21 |
20110091472 | COMPOSITIONS FOR TREATING PSORIASIS - CD40 antagonists are used to prepare compositions, including pharmaceutical compositions, for treating autoimmune and neoplastic diseases in a mammal. The CD40 antagonist compositions are useful for reversing or substantially diminishing such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and psoriasis. | 2011-04-21 |
20110091473 | NOVEL ANTIBODY THERAPIES - Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent. | 2011-04-21 |
20110091474 | Compositions and Methods For Diagnosing and Treating Diabetic Micro Vascular Complications - Disclosed herein are compositions and methods for the identification of a subject at risk for developing microvascular complications associated with diabetes such as diabetic nephropathy and diabetic retinopathy. Also disclosed is a therapeutic target for the prevention and treatment of microvascular complications associated with diabetes. | 2011-04-21 |
20110091475 | Anti-Human Interleukin-20 Antibodies - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 2011-04-21 |
20110091476 | Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors - This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided. | 2011-04-21 |
20110091477 | MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR - The invention provides methods and compositions for modulating hepatocyte growth factor activator function. | 2011-04-21 |
20110091478 | METHODS OF USING ANTIBODIES AGAINST HUMAN IL-22 - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 2011-04-21 |
20110091479 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2011-04-21 |
20110091480 | Antigen-Binding Proteins Targeting S. Aureus Orf0657n - The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an | 2011-04-21 |
20110091481 | BIOMARKERS FOR PREDICTING RESPONSE TO IMMUNOSUPPRESSIVE THERAPY - The subject invention concerns methods and materials for assessing a patient's likelihood of responsiveness to an immunosuppressive therapy. The subject invention is contemplated for use with patients having an autoimmune disorder. In an exemplified embodiment, the methods of the invention are used for assessing and/or treating a patient with MDS. In one embodiment, a method of the invention comprises analyzing T cells of a patient for dysregulation of CD4 | 2011-04-21 |
20110091482 | EXPRESSION OF KIR IN HUMAN CANCER CELLS AS A BIOMARKER FOR IMMUNO-ESCAPE AND CANCER METASTASIS - The present invention is based on the finding that the level of KIR expression in a cancer cell is significant with regard to tumor invasion and metastasis. Therefore, the present invention concerns methods and compositions for evaluating cancer in a patient based on KIR protein or mRNA expression. The invention also provides methods and compositions for treating cancer using a KIR inhibitor and methods of screening for KIR inhibitors. | 2011-04-21 |
20110091483 | Canine Anti-CD20 Antibodies - The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies. | 2011-04-21 |
20110091484 | Compositions and methods for preventing or treating a viral infection - The present invention is a composition for enhancing the immunogenicity of viral vaccine. The composition encompasses a viral vaccine in combination with at least one toll-like receptor and, in particular embodiments, an anti-CD40 antibody. The compositions of the instant invention find application in the prevention or treatment of a viral infection. | 2011-04-21 |
20110091485 | MODULATION OF CELL JUNCTIONS - The present invention provides methods of modulating cell junctions via the Gp140 membrane protein. Gp140 agonists and antagonists are provided, including activating and non-activating antibodies of Gp140, as well as compositions including the same. Methods of treatment including administration of a Gp140 agonist or antagonist are also provided. Finally, implants having a Gp140 modulator coupled thereto are provided. | 2011-04-21 |
20110091486 | INHIBITION OF POST-RADIATION TUMOR GROWTH - Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases. | 2011-04-21 |
20110091487 | MELANOMA BIOMARKER AND METHODS OF USES - The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods for cancers, other than epithelial cancers, preferably melanoma, comprising analyzing TROY expression in a biological sample from an individual or in an individual, wherein expression of TROY in non-epithelial cells, such as in melanocytes, in indicative the biological sample or the individual containing malignant cells, such as malignant melanoma cells. The invention also provides therapeutic use of TROY targeting molecules, such as TROY antibodies or TROY targeting RNA interfering agents for treatment of cancer wherein the cancer cells express TROY. | 2011-04-21 |
20110091488 | WATER-SWELLABLE POLYMERS - A pharmaceutical controlled release composition in solid dosage form is provided which comprises (I) a water-swellable linear polymer obtainable by reacting together: (a) a dried polyethylene oxide; (b) a dried C | 2011-04-21 |
20110091489 | SURVIVIN PEPTIDE VACCINE - The present invention relates to a therapeutic vaccine comprising one or more survivin polypeptide fragments. The vaccine can be used for prophylactic, ameliorating and/or curative treatment of e.g. cancer diseases. The invention further relates to methods of combination treatment. | 2011-04-21 |
20110091490 | NOVEL VACCINE FOR DOG - This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the attenuated canine adenovirus type 2 strain obtained by adapting the canine adenovirus type 2 F1 strain in cultured cells to attenuate the same, and an attenuated canine parvovirus strain obtained by adapting the canine parvovirus F3 strain in cultured cells to attenuate the same. | 2011-04-21 |
20110091491 | HIV-1 GP41 NEUTRALIZATION DOMAIN AND USE THEREOF - The invention relates to a region of the HIV-I gp41 protein that contains, at least in part, an epitope that allows potent neutralization of resistant virus particles. This site is present in the C-terminal heptad repeat region of gp41 (HR2), and adjacent to, but distinct from the MPER. Vaccines containing this region as well as monoclonal antibodies which specifically bind to this region and neutralize an HIV-I primary isolate are also provided as is a method for stimulating the formation of antibodies that neutralize infection by an HIV isolate. | 2011-04-21 |
20110091492 | ESCHERICHIA COLI IMMUNOGENS WITH IMPROVED SOLUBILITY - Variants of the pathogenic | 2011-04-21 |
20110091493 | VACCINE COMPOSITIONS AND USES THEREOF - The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects. | 2011-04-21 |
20110091494 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of | 2011-04-21 |
20110091495 | HCV E2 CONSTRUCT COMPOSITIONS AND METHODS - A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal sequence, the ectodomain of HCV E2 sequence truncated at aa 664, a thrombin cleavage site and a human Fc domain. The method also relates to an expression system for the construct, which is stably expressed in human embryonic kidney cells 293T. Continuous protein expression in a bioreactor allows for 4 mg of purified protein per liter of cell supernatant. | 2011-04-21 |
20110091496 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF VACCINES TO DISRUPTED EPITHELIUM - The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection. | 2011-04-21 |
20110091497 | Method For Identifying and Validating Dominant T Helper Cell Epitopes Using An HLA-DM-Assisted Class II Binding Assay - Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-MHC complexes are in many cases inadequate for a number of reasons. Disclosed herein is a reductionistic system incorporating known participants of MHC class II antigen processing in solution to generate peptide pools from antigens, including those for which no immunodominant epitope has yet been identified, that are highly enriched for proteolytic fragments containing their immunodominant epitopes. HLA-DM-mediated editing contributes significantly to immunodominance and is exploited in discovering immunodominant epitopes from novel or previously uncharacterized antigens, particularly antigens associated with pathogens, tumors or autoimmune diseases. | 2011-04-21 |
20110091498 | METHODS OF STIMULATING AN IMMUNE RESPONSE AGAINST PROSTATE SPECIFIC ANTIGEN - The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus. | 2011-04-21 |
20110091499 | TREATMENT OF PIGS WITH PCV2 ANTIGENT - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 2011-04-21 |
20110091500 | Inactivated Live-Attenuated Bluetongue Virus Vaccine - The invention describes the preparation of an inactivated bluetongue virus (BTV) composition, and in particular a vaccine, using an attenuated live BTV vaccine strain as masterseed. The vaccine can be administered to an animal to prevent bluetongue disease by eliciting an immune response against the bluetongue virus serotype(s) included in the composition. | 2011-04-21 |
20110091501 | Recombinant Rhinovirus Vectors - The invention provides rhinovirus vectors, which can be used in the delivery of immunogens, such as influenza virus immunogens, and corresponding compositions and methods. | 2011-04-21 |
20110091502 | HUMAN PARVOVIRUS: HUMINK PARVOVIRUS - Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Humink parvovirus, and variants thereof. Also provided are methods of detecting the Humink parvovirus and diagnosing Humink parvovirus infection, methods of treating or preventing Humink parvovirus infection, and methods for identifying anti-Humink parvovirus compounds. | 2011-04-21 |
20110091503 | Therapeutic composition with a botulinum neurotoxin - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 2011-04-21 |
20110091504 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 2011-04-21 |
20110091505 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 2011-04-21 |
20110091506 | VACCINE COMPOSITIONS - The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a | 2011-04-21 |
20110091507 | SCHISTOSOMIASIS VACCINE COMPOSITIONS AND METHODS OF USE - No effective vaccine exists for the devastating parasitic disease of Schistosomiasis. The present invention focuses on Sm-p80, a functionally important antigen of | 2011-04-21 |
20110091508 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF - The invention features oligofluorinated cross-linked polymers and their use in the manufacture of articles and coating surfaces. | 2011-04-21 |
20110091509 | Benzonatate compositions and methods of use - Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications. | 2011-04-21 |
20110091510 | NANOROD MATERIALS AND METHODS OF MAKING AND USING SAME - The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the nanorod is composed of Zinc oxide (ZnO). In a further embodiment, a nanorod of the invention further comprises SiO | 2011-04-21 |
20110091511 | TRANSDERMAL DELIVERY OF DRUGS BASED ON CRYSTAL SIZE - A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, providing drug having differing crystal sizes as well as drug which is solublized in the pressure-sensitive adhesive composition controls the rate of drug delivery from the pressure-sensitive adhesive composition. | 2011-04-21 |
20110091512 | HIGHLY POROUS, LARGE POLYMERIC PARTICLES AND METHODS OF PREPARATION AND USE - The present invention relates to porous cross-linked polymeric particles having cavities joined by interconnecting pores wherein all or nearly all of the cavities at the interior of each particle communicate with the surface of the particle. The present invention also relates to a process for producing a porous, cross-linked large polymeric particle as well as the product of this process. This process involves combining a continuous phase with an aqueous discontinuous phase to form an emulsion, then placing this emulsion into a mold to produce large particles having shapes derived from a mold, e.g., ellipsoids, spheroids, cylinders, prisms, etc. Also included in the invention are modifications of the particles as well as methods for using the particles in a variety of applications. All described methods, compositions, and articles of manufacture are within the scope of the invention. | 2011-04-21 |
20110091513 | WATER-DISPERSIBLE AND MULTICOMPONENT FIBERS FROM SULFOPOLYESTERS - Disclosed are multicomponent fibers derived from a blend of a sulfopolyester with a water non-dispersible polymer wherein the as-spun denier is less than about 6 and wherein the water dispersible sulfopolyester exhibits a melt viscosity of less than 12,000 poise measured at 240° C. at a strain rate of 1 rad/sec, and wherein the sulfopolyester comprising less than about 25 mole % of residues of at least one sulfomonomer, based on the total moles of diacid or diol residues. The multicomponent fiber is capable of being drawn at a relatively high fiber speed, particularly at least about 2000 m/min, and may be used to produce microdenier fibers. Fibrous articles may be produced from the multicomponent fibers and microdenier fibers. Also disclosed is a process for multicomponent fibers, nonwoven fabrics, and microdenier webs. | 2011-04-21 |
20110091514 | QUATERNARY OXIDES AND CATALYSTS CONTAINING QUATERNARY OXIDES - A quaternary oxide includes a dopant metal, a dopant nonmetal, titanium, and oxygen. The atomic ratio of titanium, oxygen and dopant nonmetal may be 1:0.5-1.99:0.01-1.5. Quaternary oxides may be used in catalytic compositions, in coatings for disinfecting surfaces and in coatings for self-cleaning surfaces. A method of making a quaternary oxide includes combining ingredients including a titanium source, a dopant nonmetal source, a dopant metal salt, and a polar organic solvent to form a reaction mixture; and heating the reaction mixture. | 2011-04-21 |
20110091515 | DRUG-ELUTING MEDICAL DEVICES - Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures. | 2011-04-21 |
20110091516 | Muscle-based grafts/implants - The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic gent to attract a desired cell. | 2011-04-21 |
20110091517 | BIOCOMPATIBLE SCAFFOLDS WITH TISSUE FRAGMENTS - A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair. The biocompatible tissue repair implants include a biocompatible scaffold and particles of living tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold. | 2011-04-21 |
20110091518 | IMPLANT DEVICES HAVING VARYING BIOACTIVE AGENT LOADING CONFIGURATIONS - Described herein are implant devices comprising various configurations of bioactive agent loading which can be selected and used to tailor a particular bioactive agent release profile from the implant device. | 2011-04-21 |
20110091519 | CONTROLLING RESORPTION OF BIORESORBABLE MEDICAL IMPLANT MATERIAL - The resorption of a medical implant can be controlled with the use of particles embedded in a resorbable bulk material forming the implant or portion thereof. The implant can be removed from a body of a mammal by natural biological mechanisms after use. The resorption of the implant can involve swelling and/or hydrolyzing of the particles within the implant upon contact with a body fluid such that porosity and flow of fluid within the bulk material of the implant is increased. Resorption of the implant may also involve the use of particles with magnetic properties embedded within the implant such that an applied magnetic field causes the particles to vibrate within the bulk material thereby increasing the porosity and thus the flow of fluid, hence facilitating resorption of the implant. The resorption rate of the implant can be controlled by modulating swelling, hydrolysis, or movement of the embedded particles. | 2011-04-21 |
20110091520 | Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies - Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma. | 2011-04-21 |
20110091521 | Edible spoon for dissociating into consumable predetermined clumps in order to prevent dissociating into random granules that would make consumption more difficult - An edible spoon for dissociating into consumable predetermined clumps in order to prevent dissociating into random granules that would make consumption more difficult. The edible spoon includes a bowl and a handle. The bowl extends from the handle and contains weakened lines. The weakened lines in the bowl define the consumable predetermined clumps so as to allow the bowl to dissociate into the consumable predetermined clumps in order to prevent dissociating into the random granules that would make the consumption more difficult. | 2011-04-21 |
20110091522 | Edible chew pill jacket - An edible chew pill jacket receives a pill/tablet or capsule that is to be administered to a pet, animal or human. The edible chew pill jacket includes a flexible top wall, side walls and bottom wall configured to form a chamber appointed to receive a pill. A flexible longitudinal slit is integrated within the top wall for providing access to the chamber for insertion of the pill within the edible chew pill jacket. The edible chew pill jacket is formulated with at least one flavoring to provide a tasty treat appointed to mask the pill's taste. The chew pill jacket substantially encapsulates the pill/tablet appointed to be orally ingested. The chew pill jacket may include medicament therein, nutrients, vitamins, or may simply be provided as a tasty treat to mask the taste of the pill. | 2011-04-21 |
20110091523 | Cochleate compositions directed against expression of proteins - Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions. | 2011-04-21 |
20110091524 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY - The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment. | 2011-04-21 |
20110091525 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF - The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP. | 2011-04-21 |
20110091526 | Parasite Vaccine - Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein. | 2011-04-21 |
20110091527 | COMPOSITIONS AND METHODS FOR REDUCING SCAR FORMATION IN WOUND HEALING - The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof. The healing wound may be a skin damage, but it may also be a myocardium e.g. which is at risk of suffering or is recovering from a heart failure. | 2011-04-21 |
20110091528 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 2011-04-21 |
20110091529 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS - The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine. | 2011-04-21 |
20110091530 | OLIGOPEPTIDE TYROSINASE INHIBITORS AND USES THEREOF - Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK (SEQ ID NO: 1) and YRSRKYSSWY (SEQ ID NO: 2). | 2011-04-21 |
20110091531 | Cooling Composition - A liquid cooling composition, which is a mixture of at least one primary cooling compound, at least one different secondary cooling compound and at least one ingestible non-polar solvent for the primary cooling compound, the weight ratios of primary cooling compound:secondary cooling compound:solvent being 1:1.5-2.25:2-4.4. | 2011-04-21 |
20110091532 | COMPOSITION FOR THE TREATMENT OF ARTHRITIS CONTAINING A DIBENZO-P-DIOXIN DERIVATIVE AS THE ACTIVE INGREDIENT - Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis. | 2011-04-21 |
20110091533 | Amphiphilic polymer capsules and related methods of interfacial assembly - Polymer capsules from amphiphilic graft copolymers comprising reactive, hydrophobic polyolefin backbones, and hydrophilic poly(ethylene glycol) (PEG) grafts are produced by self-assembly of the polymers at the oil-water interface, and crosslinking the assembly with bis-cyclooctene PEG derivatives in conjunction with ring-open metathesis polymerization catalysts. The use of the graft copolymer architecture in capsule synthesis provides significant opportunities to tune both the surface properties, in terms of recognition, and the membrane properties, in terms of mechanical strength, encapsulation, and release. | 2011-04-21 |
20110091534 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. | 2011-04-21 |
20110091535 | SOLID PHARMACEUTICAL FORMULATION - The present invention relates to a sustained-release solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch in an amount of 10 to 90% by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredients. | 2011-04-21 |
20110091536 | COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF - Oral pharmaceutical compositions comprising dry extract of | 2011-04-21 |
20110091537 | Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile - The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 μm, and are formed by a core containing at least said active ingredient and coated with at least one coating layer,
| 2011-04-21 |
20110091538 | POLYMER ADAPTED TO RELEASE BIOACTIVE AGENTS IN VIVO, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION THEREOF - The present invention provides a Monodisperse Polymer Particles (MPP) adapted to release alkoxy groups by means of a hydrolyser, such that Monodisperse Bioactive Polymer Particles (MBPP) are obtained in vivo. The MBPP are characterized by (a) at least one naturally occurring or synthetic long molecular chain consisting of biologically stable backbones optionally crosslinked, further characterized by a molecular weight of at least 1 KD, comprising between 10 to 1,000,000 repeated covalently-linked small molecules with a functionality of at least one alkoxy releasing group per molecule; (b) a long dimension between 0.1 and 10 micrometers; and, (c) a zeta potential value of 30 to 130 mV at pH of about 7.0. The MBPP alter, inhibit, activate, induce or otherwise affect biological or chemical events in vivo. | 2011-04-21 |
20110091539 | Micronized Tanaproget and Compositions Containing Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 2011-04-21 |
20110091540 | POLYMERIC COMPOSITIONS AND THEIR METHOD OF USE IN COMBINATION WITH ACTIVE AGENTS - A combination of active agents is disclosed which are particularly useful for treating fluid overload conditions. Methods for using the combination of active agent are also disclosed. The combination can include a highly absorbent polyelectrolyte polymer along with an agent that increases the amount of fluid in the intestine. | 2011-04-21 |
20110091541 | Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications - Preparation of AT1 receptors antagonists formulations using the cyclodextrins, their derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular disease and their complications. Until now, no applications using the AT1 | 2011-04-21 |
20110091542 | BACLOFEN AND R-BACLOFEN GASTRORETENTIVE DRUG DELIVERY SYSTEMS - A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide fast onset of baclofen or R-baclofen activity with prolonged absorption and minimal undesirable side effects. | 2011-04-21 |
20110091543 | ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS - Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally. | 2011-04-21 |
20110091544 | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting - Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the same are provided. | 2011-04-21 |
20110091545 | Direct Injection moldable and rapidly disintegrating tablet matrix - The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth. | 2011-04-21 |
20110091546 | COMPOSITION FOR RAPID DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. | 2011-04-21 |
20110091547 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 2011-04-21 |
20110091548 | USE OF A MATRIX FOR ORALLY ADMINISTERING SUSTAINED RELEASE MAGNESIUM, AND COMPOSITION CONTAINING SAID MATRIX - A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica. A non-enteric protective coating that slows down the gastric dissolution of the magnesium may comprise 15 to 75 parts by weight of shellac, cellulose ether or a mixture thereof. The tablet may be administered to patients in need thereof. | 2011-04-21 |
20110091549 | Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels - Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and the physiologic environment in which the hydrogel is placed. | 2011-04-21 |